Ep190: Neil Kumar on Building a Rare Disease Drug Company
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
--------
1:13:12
--------
1:13:12
Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
--------
1:12:33
--------
1:12:33
Ep188: Art Krieg on Innate Immune System Activators for Cancer
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
--------
1:09:05
--------
1:09:05
Ep187: Eric Fischer on Creating a New Class of Medicines
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
--------
1:05:48
--------
1:05:48
Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Netherlands